[go: up one dir, main page]

MX2019012606A - Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. - Google Patents

Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.

Info

Publication number
MX2019012606A
MX2019012606A MX2019012606A MX2019012606A MX2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A
Authority
MX
Mexico
Prior art keywords
cd3xegfr
bispecific antibodies
seq
treatment
egfr
Prior art date
Application number
MX2019012606A
Other languages
English (en)
Inventor
STUTZ Cian
Lissilaa Rami
Blein Stanislas
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of MX2019012606A publication Critical patent/MX2019012606A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona a anticuerpos biespecíficos que se unen a CD3 y EGFR simultáneamente. Esta clase de anticuerpo ha demostrado por los inventores ser útil en el tratamiento de tumores EGFR al redirigir las células T y formar una sinapsis inmune entre las células T activadas y EGFR que expresan células tumorales, llevando a mayores niveles de matanza de células tumolares que expresan EGFR. En particular la presente invención se relaciona a anticuerpos biespecíficos de CD3xEGFR_SF4 (SEQ ID NO: 4, 5 y 9), CD3xEGFR_SD1 (SEQ ID NO: 1, 2 y 10) y CD3xEGFR_SD2 (SEQ ID NO: 11, 10 y 2).
MX2019012606A 2017-04-24 2018-04-24 Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. MX2019012606A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17167709 2017-04-24
PCT/EP2018/060488 WO2018197502A1 (en) 2017-04-24 2018-04-24 T cell redirecting bispecific antibodies for the treatment of egfr positive cancers

Publications (1)

Publication Number Publication Date
MX2019012606A true MX2019012606A (es) 2019-12-02

Family

ID=58632245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012606A MX2019012606A (es) 2017-04-24 2018-04-24 Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.

Country Status (11)

Country Link
US (1) US20230159661A1 (es)
EP (1) EP3615571A1 (es)
JP (1) JP2020517659A (es)
KR (1) KR20200002886A (es)
CN (1) CN110831968A (es)
AU (1) AU2018259039A1 (es)
CA (1) CA3060190A1 (es)
EA (1) EA201992143A1 (es)
MX (1) MX2019012606A (es)
SG (2) SG10201912545PA (es)
WO (1) WO2018197502A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160090308A (ko) * 2013-11-04 2016-07-29 그렌마크 파머수티칼스 에스. 아. T 세포 재표적 이형-이량체 면역글로불린의 생산
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
US20250228894A2 (en) * 2021-02-16 2025-07-17 City Of Hope Truncated domain iv egfr and uses thereof
WO2023183766A1 (en) * 2022-03-20 2023-09-28 Abcellera Biologics Inc. Anti-cd3 antibodies and t-cell engagers and methods of use
KR20240163751A (ko) * 2022-03-30 2024-11-19 파인트리 테라퓨틱스 인코포레이티드 Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법
CN114621351B (zh) * 2022-04-27 2023-01-03 华羊生物技术股份有限公司 多特异性抗体及其治疗癌症的用途
EP4562042A1 (en) * 2022-07-30 2025-06-04 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用
CN119936402B (zh) * 2025-01-14 2025-09-23 上海大学 一种完全基于金抗体的检测egfr的酶联免疫试剂盒及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101626988B1 (ko) * 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
US10329350B2 (en) * 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
HK1211299A1 (en) * 2013-02-26 2016-05-20 罗切格利卡特公司 Bispecific t cell activating antigen binding molecules
JP6694808B2 (ja) * 2013-04-19 2020-05-20 コバジェン アーゲーＣｏｖａｇｅｎ Ａｇ 抗腫瘍活性を有する新規な二重特異的結合分子
CN104341504B (zh) * 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
KR20160090308A (ko) * 2013-11-04 2016-07-29 그렌마크 파머수티칼스 에스. 아. T 세포 재표적 이형-이량체 면역글로불린의 생산
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
CN104774268B (zh) * 2015-01-21 2018-09-28 武汉友芝友生物制药有限公司 一种双特异性抗体egfr×cd3的构建及应用

Also Published As

Publication number Publication date
KR20200002886A (ko) 2020-01-08
EP3615571A1 (en) 2020-03-04
US20230159661A1 (en) 2023-05-25
SG10201912545PA (en) 2020-02-27
JP2020517659A (ja) 2020-06-18
WO2018197502A1 (en) 2018-11-01
EA201992143A1 (ru) 2020-03-13
AU2018259039A1 (en) 2019-11-07
SG11201909498XA (en) 2019-11-28
CA3060190A1 (en) 2018-11-01
CN110831968A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
MX2019012606A (es) Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
PH12020551211A1 (en) Antibodies binding to gprc5d
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
PH12019502640A1 (en) Antibodies specific for flt3 and their uses
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
NZ774111A (en) Antibodies binding to cd3
MY206610A (en) Antibodies binding to gprc5d
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
MY202516A (en) Antibodies to tigit
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
WO2020121195A8 (en) Trem2 antibodies and uses thereof
UA120060C2 (uk) Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
ZA202101495B (en) Chimeric antigen receptor
SA520411577B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
AU2018230657A8 (en) Anti-C5 antibodies and uses thereof
JOP20180021A1 (ar) الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
PH12019502274A1 (en) Antibodies binding to steap-1
PH12021550244A1 (en) Anti-btla antibody
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2021004454A (es) Anticuerpos anti-sinucleina.
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells